Related references
Note: Only part of the references are listed.Breaking the Silence: Exploring the Potential Effects of Explicit Instructions on Incorporating Income and Leisure in TTO Exercises
Marieke Krol et al.
VALUE IN HEALTH (2009)
Do individuals consider expected income when valuing health states?
Thomas Davidson et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2008)
Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression
Judith E. Bosmans et al.
JOURNAL OF AFFECTIVE DISORDERS (2008)
Cost-effectiveness of transcranial magnetic stimulation vs. electroconvulsive therapy for severe depression: A multi-centre randomised controlled trial
Martin Knapp et al.
JOURNAL OF AFFECTIVE DISORDERS (2008)
Cost-effectiveness of quality improvement programs for patients with subthreshold depression or depressive disorder
Kenneth B. Wells et al.
PSYCHIATRIC SERVICES (2007)
Adjuvant occupational therapy for work-related major depression works: randomized trial including economic evaluation
Aart H. Schene et al.
PSYCHOLOGICAL MEDICINE (2007)
Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder
Bruno Fantino et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2007)
Cost effectiveness of a pharmacy-based coaching programme to improve adherence to antidepressants
Judith E. Bosmans et al.
PHARMACOECONOMICS (2007)
Quality-of-life assessment when there is a loss of income
John Myers et al.
MEDICAL DECISION MAKING (2007)
The economic impact of introducing serotonin-noradrenaline reuptake inhibitors into the Brazilian national drug formulary - Cost-effectiveness and budget-impact analyses
Marcio Machado et al.
PHARMACOECONOMICS (2007)
A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care
Jan Sorensen et al.
NORDIC JOURNAL OF PSYCHIATRY (2007)
The costs and benefits of enhanced depression care to employers
Philip S. Wang et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Model to assess the cost-effectiveness of new treatments for depression
Patrik Sobocki et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2006)
Cost-effectiveness of a preventive counseling and support package for postnatal depression
Stavros Petrou et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2006)
A dollar is a dollar is a dollar - or is it?
Werner B. F. Brouwer et al.
VALUE IN HEALTH (2006)
Cost-effectiveness of a primary care treatment program for depression in low-income women in Santiago, Chile
Ricardo Araya et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Cost-effectiveness of referral for generic care or problem-solving treatment from community mental health nurses, compared with usual general practitioner care for common mental disorders - Randomised controlled trial
T. Kendrick et al.
BRITISH JOURNAL OF PSYCHIATRY (2006)
Cost-effectiveness of preventing depression in primary care patients - Randomised trial
F Smit et al.
BRITISH JOURNAL OF PSYCHIATRY (2006)
Effectiveness and cost-effectiveness of antidepressant treatment in primary health care:: A six-month randomised study comparing fluoxetine to imipramine
A Serrano-Blanco et al.
JOURNAL OF AFFECTIVE DISORDERS (2006)
Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine - Randomised controlled trial
T Kendrick et al.
BRITISH JOURNAL OF PSYCHIATRY (2006)
Productivity costs in health-state valuations - Does explicit instruction matter?
M Krol et al.
PHARMACOECONOMICS (2006)
Managed care and systems cost-effectiveness -: Treatment for depression
M Alegría et al.
MEDICAL CARE (2005)
Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder
M van Baardewijk et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Gender patterns in cost effectiveness of quality improvement for depression: Results of a randomized, controlled trial
M Schoenbaum et al.
JOURNAL OF AFFECTIVE DISORDERS (2005)
Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women
DA Revicki et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
One size fits some: the impact of patient treatment attitudes on the cost-effectiveness of a depression primary-care intervention
JM Pyne et al.
PSYCHOLOGICAL MEDICINE (2005)
A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom
AG Wade et al.
CLINICAL THERAPEUTICS (2005)
A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK
AG Wade et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Valuing patient and caregiver time - A review of the literature
JE Tranmer et al.
PHARMACOECONOMICS (2005)
Cost-effectiveness of enhancing primary care depression management on an ongoing basis
K Rost et al.
ANNALS OF FAMILY MEDICINE (2005)
Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder
JL Fernandez et al.
PHARMACOECONOMICS (2005)
A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium
K Demyttenaere et al.
CLINICAL THERAPEUTICS (2005)
Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial
P McCrone et al.
BRITISH JOURNAL OF PSYCHIATRY (2004)
Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression
MEH Hemels et al.
ANNALS OF PHARMACOTHERAPY (2004)
Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria
MEH Hemels et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder
MH Trivedi et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2004)
A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions
PW Sullivan et al.
CNS DRUGS (2004)
Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK
A Lenox-Smith et al.
PHARMACOECONOMICS (2004)
The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care
R Romeo et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2004)
The economic burden of depression in the United States: How did it change between 1990 and 2000?
PE Greenberg et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)
Cost-effectiveness of a primary care depression intervention
JM Pyne et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2003)
Cost-effectiveness of collaborative care for depression in a primary care veteran population
CF Liu et al.
PSYCHIATRIC SERVICES (2003)
When the cradle falls II: the cost-effectiveness of treating postnatal depression in a psychiatric day hospital compared with routine primary care
E Boath et al.
JOURNAL OF AFFECTIVE DISORDERS (2003)
Use of cognitive therapy for relapse prevention in chronic depression - Cost-effectiveness study
J Scott et al.
BRITISH JOURNAL OF PSYCHIATRY (2003)
A randomized controlled trial to evaluate the effectiveness and cost-effectiveness of psychodynamic counselling for general practice patients with chronic depression
S Simpson et al.
PSYCHOLOGICAL MEDICINE (2003)
Counseling versus antidepressant therapy for the treatment of mild to moderate depression in primary care - Economic analysis
P Miller et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2003)
Cost-effectiveness of a program to prevent depression relapse in primary care
GE Simon et al.
MEDICAL CARE (2002)
Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs
G Browne et al.
JOURNAL OF AFFECTIVE DISORDERS (2002)
Cost-effectiveness of a collaborative care program for primary care patients with persistent depression
GE Simon et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Cost-effectiveness of practice-initiated quality improvement for depression -: Results of a randomized controlled trial
M Schoenbaum et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
The cost-utility of screening for depression in primary care
M Valenstein et al.
ANNALS OF INTERNAL MEDICINE (2001)
Dealing with skewed data: An example using asthma-related costs of medicaid clients
KL Rascati et al.
CLINICAL THERAPEUTICS (2001)
Cost-effectiveness of systematic depression treatment for high utilizers of general medical care
GE Simon et al.
ARCHIVES OF GENERAL PSYCHIATRY (2001)
Affective disorders and suicide risk: A reexamination
JM Bostwick et al.
AMERICAN JOURNAL OF PSYCHIATRY (2000)
Measuring costs in cost-utility analyses -: Variations in the literature
PW Stone et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2000)
Costs and effectiveness of community postnatal support workers: randomised controlled trial
CJ Morrell et al.
BRITISH MEDICAL JOURNAL (2000)
Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK
J Borghi et al.
EUROPEAN PSYCHIATRY (2000)
Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom
H Freeman et al.
PHARMACOECONOMICS (2000)
On the economic foundations of CEA. Ladies and gentlemen, take your positions!
WBF Brouwer et al.
JOURNAL OF HEALTH ECONOMICS (2000)
Randomised trial of monitoring, feedback, and management of care by telephone to improve treatment of depression in primary care
GE Simon et al.
BRITISH MEDICAL JOURNAL (2000)
Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial
JA Sacristan et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2000)
Share Paper
